Topic: drug costs

opdivo

Opdivo falls short at NICE, thanks to Inlyta discount

England’s cost-effectiveness watchdogs have a love-hate relationship with Opdivo, the hot Bristol-Myers cancer treatment. A new Opdivo cocktail recently won a quick thumbs up in melanoma from NICE’s influential gatekeepers, but now they've stiff-armed the drug in kidney cancer.